Patents Expiring in July 2037
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | SAXENDA | liraglutide | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | AP2 | RX | Yes | Yes | 9,968,659*PED | ⤷ Get Started Free | Y | |||
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | AP1 | RX | Yes | Yes | 9,968,659*PED | ⤷ Get Started Free | Y | |||
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-001 | Jan 27, 2012 | RX | Yes | No | 10,869,924*PED | ⤷ Get Started Free | Y | ||||
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-002 | Jan 27, 2012 | RX | Yes | Yes | 10,869,924*PED | ⤷ Get Started Free | Y | ||||
| Botanix Sb | SOFDRA | sofpironium bromide | GEL, METERED;TOPICAL | 217347-001 | Jun 18, 2024 | RX | Yes | Yes | 11,123,325 | ⤷ Get Started Free | Y | TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
